Baidu
map

Int J Urol:上尿路上皮癌根治术后对侧上尿路复发预测因素调查

2021-11-09 AlexYang MedSci原创

探讨了上尿路癌根治性肾切除术后对侧上尿路复发的关键预测因素。

尿道癌是一种源于尿道上皮的恶性肿瘤疾病,可能涉及下尿路(膀胱、前列腺和尿道)和上尿路(肾盏、肾盂和输尿管)。UTUC约占所有尿路上皮癌的5%。RNU与膀胱袖口状切除术是局部UTUC的标准治疗方法。据已发表的文献,这两种手术的术后复发率很高,主要包括膀胱复发、局部复发和CUTR。由于膀胱复发很常见,因此已有广泛研究。

近期,《Int J Urol》杂志上发表了一篇文章,探讨了上尿路癌根治性肾切除术后对侧上尿路复发的关键预测因素

在2001年1月至2015年12月期间,研究人员将548名在单一机构接受根治性肾切除术的上尿路上皮癌患者纳入了研究。他们调查了一些临床病理特征和结果。关键的终点是根治性肾切除术后的对侧上尿路复发的诊断情况。

在这548名患者中,中位年龄为68岁(范围24-93岁),RNU后的中位随访时间为41个月(范围8-191个月),男性患者有237名(43.2%)。其中,328名患者(59.9%)的年龄大于65岁,389名患者(71%)从不吸烟。128名患者(23.4%)的术前肾功能不佳(eGFR<30 mL/ min/1.73 m2)。共有71名患者(13%)有尿毒症病史,其中7名患者(9.9%)曾接受过肾脏移植手术。212名患者(38.7%)存在肿瘤多灶性。CUTR 在28名患者(5.1%)中发生。

RNU和CUTR之间的中位时间间隔为15.4个月(范围3.4- 52.4个月)。总生存率和UTUC特异性生存率不受CUTR的影响。总共有13个临床病理参数确定为CUTR的重要预测因素。在单变量分析中,eGFR<30(HR 3.23,P=0.002)和肿瘤多灶性(HR 2.30,P=0.029)显示出统计学显著性。Cox回归模型多变量分析表明,eGFR<30(HR 3.08,P=0.003) 和肿瘤多灶性(HR 2.16,P=0.043)仍是CUTR的重要预测因素。

预测CUTR临床病理参数的单变量和多变量分析

综上所述,术前估计肾小球滤过率<30和肿瘤多灶性是上尿路癌根治性肾切除术后对侧上尿路复发的重要预测因素

原始出处:

Chuan-Shu Chen , Jian-Ri Li , Cheng-Kuang Yang et al. Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol. Oct 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077300, encodeId=a2e720e73007c, content=<a href='/topic/show?id=c0d01985103' target=_blank style='color:#2F92EE;'>#上尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19851, encryptionId=c0d01985103, topicName=上尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 05 17:42:48 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264385, encodeId=9ed112643851f, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399763, encodeId=a1851399e63a8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539405, encodeId=8c47153940511, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586265, encodeId=754f158626590, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077300, encodeId=a2e720e73007c, content=<a href='/topic/show?id=c0d01985103' target=_blank style='color:#2F92EE;'>#上尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19851, encryptionId=c0d01985103, topicName=上尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 05 17:42:48 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264385, encodeId=9ed112643851f, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399763, encodeId=a1851399e63a8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539405, encodeId=8c47153940511, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586265, encodeId=754f158626590, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077300, encodeId=a2e720e73007c, content=<a href='/topic/show?id=c0d01985103' target=_blank style='color:#2F92EE;'>#上尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19851, encryptionId=c0d01985103, topicName=上尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 05 17:42:48 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264385, encodeId=9ed112643851f, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399763, encodeId=a1851399e63a8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539405, encodeId=8c47153940511, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586265, encodeId=754f158626590, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077300, encodeId=a2e720e73007c, content=<a href='/topic/show?id=c0d01985103' target=_blank style='color:#2F92EE;'>#上尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19851, encryptionId=c0d01985103, topicName=上尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 05 17:42:48 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264385, encodeId=9ed112643851f, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399763, encodeId=a1851399e63a8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539405, encodeId=8c47153940511, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586265, encodeId=754f158626590, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2077300, encodeId=a2e720e73007c, content=<a href='/topic/show?id=c0d01985103' target=_blank style='color:#2F92EE;'>#上尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19851, encryptionId=c0d01985103, topicName=上尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 05 17:42:48 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264385, encodeId=9ed112643851f, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399763, encodeId=a1851399e63a8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539405, encodeId=8c47153940511, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586265, encodeId=754f158626590, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Nov 04 11:42:48 CST 2021, time=2021-11-04, status=1, ipAttribution=)]
    2021-11-04 jeanqiuqiu

相关资讯

腹腔镜胃癌根治术的优势有哪些?

在我国胃癌的发病率很高,然而胃癌的早期诊断率比较低,给胃癌的治疗带来不便。那么您了解胃癌吗? 胃癌的诱发因素众多,如地域环境、饮食生活方式(长期食用盐腌、熏烤食品)、幽门螺杆菌感染、慢性疾患及遗传等因素。胃癌按照肿瘤侵犯程度的不同可分为早期胃癌和进展期胃癌。

Eur Radiol:肝癌根治术后短期又出现了复发,如何在术前评估一下呢?

对于肝功能储备良好的HCC患者,尤其是早期HCC,根治性切除术是普遍认为的最佳治疗方式。然而,由于术后的高复发率,HCC患者的长期预后仍不令人满意。

病例:特瑞普利单抗联合化疗新辅助治疗获PR,初始手术困难的食管鳞癌患者成功施行根治术

免疫治疗在食管癌中进展迅速,已在晚期食管癌患者的二线及以上治疗中表现出较化疗更优的生存结果。其在食管癌一线治疗中的研究也有多项在进行中。不仅如此,鉴于免疫治疗的治疗潜力,其与化疗、化放疗联合用于可切除食管癌新辅助治疗的研究也取得了初步成果,为局部晚期的患者带来了获益可能。本文介绍的这例食管癌患者,初始手术切除有困难,经PD-1单抗特瑞普利单抗联合化疗新辅助治疗后,原发灶明显缩小,得以成功实施根治性

一例AIDS患者食管癌根治术中气管撕裂的麻醉管理体会

患者,男,58岁,身高171 cm,体重64kg。因“吞咽困难2月余,确诊食管癌3d”入院。患者2个多月前无明显诱因下开始出现进食哽咽,进食后约2秒后有异物感,伴胸骨后不适感,并逐渐出现吞咽困难症状,当时未重视。1个月前,无法进食较大块食物,伴恶心,并出现呕吐进食物品,能进半流质及流质饮食,但较硬食物难以下咽。无反酸、嗳气,无胸骨后灼烧痛,无发热、恶寒,无腹胀、腹泻,食量减少至原来的1/2。在外院

SCI REP:前列腺癌根治术后盆底重建改选什么方法?

由此可见,接受根治性前列腺切除术的患者并且采用后路重建治疗尿失禁出现最少。采用前壁悬吊、前路重建联合后路重建治疗和前壁悬吊联合后路重建治疗在术后没有观察到明显的益处。

Int J Cancer:新辅助系统疗法对胃肠道间质瘤预后的影响

予以局限性GIST患者新辅助系统疗法与适度的生存益处和较低的术后90天死亡率相关,且不影响R0切除的可能性。

Baidu
map
Baidu
map
Baidu
map